Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ALB | P02768 | 1/20 | 0.32 |
| ▸ | ARG1 | P05089 | 2/20 | 0.30 |
| ▸ | ARG2 | P78540 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27751170 | 0.85 | ALOX15 (0.40) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL161929 | 0.81 | ARG1 (0.47) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL6431682 | 0.81 | ARG1 (0.47) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL7277920 | 0.81 | ALOX15 (0.38) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL28637035 | 0.81 | ALOX15 (0.38) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL202490 | 0.81 | ARG1 (0.47) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL3692819 | 0.81 | ALOX15 (0.35) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL23094075 | 0.80 | ODC1 (0.44) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL11674300 | 0.80 | ARG1 (0.46) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL23094070 | 0.80 | ODC1 (0.44) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112740045-A | Markers for the risk of developing insulin resistance in childhood and adolescence | 雀巢产品有限公司 | 2021-04-30 | — | — | CN | disclosed |
| EP-2000474-B1 | METHOD FOR PRODUCTION OF PEPTIDE THIOESTER COMPOUND | GLYTECH INC (JP) | 2017-11-01 | — | — | EP | disclosed |
| US-20150197500-A1 | NO-RELEASING GUANIDINE-CHROMENE CONJUGATES | EUCLISES PHARMACEUTICALS INC (US) | 2015-07-16 | — | — | US | disclosed |
| US-20140322160-A1 | METHOD AND COMPOSITION FOR ALTERING A B CELL MEDIATED PATHOLOGY | MMRGLOBAL, INC. (US) | 2014-10-30 | — | — | US | disclosed |
| US-8637638-B2 | Method and composition for altering a B cell mediated pathology | MMRGLOBAL, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| EP-1309347-B1 | METHOD AND COMPOSITION FOR ALTERING A B CELL MEDIATED PATHOLOGY | MMRGLOBAL INC (US) | 2013-02-27 | — | — | EP | disclosed |
| US-20120114593-A1 | METHOD AND COMPOSITION FOR ALTERING A B CELL MEDIATED PATHOLOGY | MMR GLOBAL, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-8133486-B2 | Method and composition for altering a B cell mediated pathology | MMRGLOBAL, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-8114404-B2 | Method and composition for altering a B cell mediated pathology | MMRGLOBAL, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-8058394-B2 | Method for production of peptide thioester compound | OTSUKA CHEMICAL CO., LTD. (JP) | 2011-11-15 | — | — | US | disclosed |
| US-20030082178-A1 | Administering chimera protein | MMRGLOBAL, INC. | 2003-05-01 | — | — | US | disclosed |
| EP-1294901-A2 | NOVEL PROTEASES | Sugen, Inc. (US) | 2003-03-26 | — | — | EP | disclosed |
| US-20030012782-A1 | Method and composition for altering a T cell mediated pathology | FAVRILLE, INC. | 2003-01-16 | — | — | US | disclosed |
| US-20020064856-A1 | Novel proteases | SUGEN, INC. | 2002-05-30 | — | — | US | disclosed |
| WO-2002013861-A2 | METHOD AND COMPOSITION FOR ALTERING A T CELL MEDIATED PATHOLOGY | FAVRILLE, INC. (US) | 2002-02-21 | — | — | WO | disclosed |
| WO-2002000860-A2 | NOVEL PROTEASES | SUGEN, INC. (US) | 2002-01-03 | — | — | WO | disclosed |
| WO-2001083782-A2 | NOVEL PROTEASES | SUGEN, INC. (US) | 2001-11-08 | — | — | WO | disclosed |
| US-5604094-A | GENETIC ENGINEERED POLYNUCLEOTIDE | NEW YORK UNIVERSITY (US) | 1997-02-18 | — | — | US | disclosed |
| EP-0277561-B1 | NEW ARGININE DERIVATIVE, PROCESS FOR THE PREPARATION THEREOF AND ITS USE IN PEPTIDE SYNTHESIS | ENIRICERCHE S.p.A. (IT) | 1992-04-15 | — | — | EP | disclosed |
| EP-0277561-A1 | New arginine derivative, process for the preparation thereof and its use in peptide synthesis | ENIRICERCHE S.p.A. (IT) | 1988-08-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150197500-A1 | NO-RELEASING GUANIDINE-CHROMENE CONJUGATES | ARG1, ARGLU1, CGAS | ALOX15 1979/4885MEN1 1271/4885CYP1A2 540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.